HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 | Zendy

Till Schoofs | Zendy; Florian Klein | Zendy; Malte Braunschweig | Zendy; Edward F. Kreider | Zendy; Anna Feldmann | Zendy; Lilian Nogueira | Zendy; Thiago Y. Oliveira | Zendy; Julio C. C. Lorenzi | Zendy; Erica H. Parrish | Zendy; Gerald H. Learn | Zendy; Anthony P. West | Zendy; Pamela J. Björkman | Zendy; Sarah J. Schlesinger | Zendy; Michael S. Seaman | Zendy; Julie Czartoski | Zendy; M. Juliana McElrath | Zendy; Nico Pfeifer | Zendy; Beatrice H. Hahn | Zendy; Marina Caskey | Zendy; Michel C. Nussenzweig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

Author(s) -

Till Schoofs,

Florian Klein,

Malte Braunschweig,

Edward F. Kreider,

Anna Feldmann,

Lilian Nogueira,

Thiago Y. Oliveira,

Julio C. C. Lorenzi,

Erica H. Parrish,

Gerald H. Learn,

Anthony P. West,

Pamela J. Björkman,

Sarah J. Schlesinger,

Michael S. Seaman,

Julie Czartoski,

M. Juliana McElrath,

Nico Pfeifer,

Beatrice H. Hahn,

Marina Caskey,

Michel C. Nussenzweig

Publication year - 2016

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.aaf0972

Subject(s) - viremia , virology , neutralizing antibody , antibody , immunology , heterologous , immune system , monoclonal antibody , immunity , immunotherapy , humoral immunity , human immunodeficiency virus (hiv) , biology , medicine , biochemistry , gene

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research